Iain Michael  Brown net worth and biography

Iain Brown Biography and Net Worth

CFO of Alkermes
Iain Brown serves as Alkermes’ Senior Vice President, Chief Financial Officer. In this role, Mr. Brown leads the management of the Finance organization as well as the Business Planning, Procurement and Strategic Sourcing functions.

Mr. Brown has 25 years of financial experience within the biopharmaceutical industry. He previously served as Senior Vice President of Finance and Chief Accounting Officer at Alkermes. Before joining Alkermes in 2003, Mr. Brown managed EMD Serono’s North American financial operations, after being Group Corporate Controller based in Geneva, Switzerland. He also previously served as Audit Manager at PricewaterhouseCoopers.

Mr. Brown earned a bachelor’s degree in Business Studies from the University of Bradford, England and is a Chartered Accountant.

What is Iain Michael Brown's net worth?

The estimated net worth of Iain Michael Brown is at least $1.36 million as of April 19th, 2021. Mr. Brown owns 48,570 shares of Alkermes stock worth more than $1,355,589 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Brown may own. Additionally, Mr. Brown receives an annual salary of $950,880.00 as CFO at Alkermes. Learn More about Iain Michael Brown's net worth.

How old is Iain Michael Brown?

Mr. Brown is currently 55 years old. There are 6 older executives and no younger executives at Alkermes. The oldest executive at Alkermes is Dr. Floyd E. Bloom M.D., Founder, who is 87 years old. Learn More on Iain Michael Brown's age.

What is Iain Michael Brown's salary?

As the CFO of Alkermes plc, Mr. Brown earns $950,880.00 per year. There are 4 executives that earn more than Mr. Brown. The highest earning executive at Alkermes is Mr. Richard F. Pops, Chairman & CEO, who commands a salary of $2,610,000.00 per year. Learn More on Iain Michael Brown's salary.

How do I contact Iain Michael Brown?

The corporate mailing address for Mr. Brown and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Iain Michael Brown's contact information.

Has Iain Michael Brown been buying or selling shares of Alkermes?

Iain Michael Brown has not been actively trading shares of Alkermes within the last three months. Most recently, Iain Michael Brown sold 34,792 shares of the business's stock in a transaction on Monday, April 19th. The shares were sold at an average price of $20.00, for a transaction totalling $695,840.00. Following the completion of the sale, the chief financial officer now directly owns 48,570 shares of the company's stock, valued at $971,400. Learn More on Iain Michael Brown's trading history.

Who are Alkermes' active insiders?

Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.

Are insiders buying or selling shares of Alkermes?

During the last year, insiders at the sold shares 3 times. They sold a total of 79,884 shares worth more than $2,376,526.01. The most recent insider tranaction occured on November, 11th when EVP Craig C Hopkinson sold 58,996 shares worth more than $1,774,599.68. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.

Information on this page was last updated on 11/11/2024.

Iain Michael Brown Insider Trading History at Alkermes

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2021Sell34,792$20.00$695,840.0048,570View SEC Filing Icon  
4/16/2021Sell208$19.99$4,157.9248,570View SEC Filing Icon  
5/13/2020Sell6,250$15.39$96,187.5044,831View SEC Filing Icon  
12/29/2017Sell10,652$54.81$583,836.12View SEC Filing Icon  
12/29/2017Sell10,652$54.81$583,836.1216,943View SEC Filing Icon  
9/6/2016Sell29,976$45.92$1,376,497.9225,696View SEC Filing Icon  
4/18/2016Sell5,368$39.27$210,801.3651,822View SEC Filing Icon  
10/29/2015Sell10,822$69.99$757,431.7838,689View SEC Filing Icon  
See Full Table

Iain Michael Brown Buying and Selling Activity at Alkermes

This chart shows Iain Michael Brown's buying and selling at Alkermes by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alkermes Company Overview

Alkermes logo
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $27.91
Low: $27.37
High: $28.29

50 Day Range

MA: $27.84
Low: $25.70
High: $30.08

2 Week Range

Now: $27.91
Low: $22.22
High: $32.88

Volume

1,694,996 shs

Average Volume

1,954,297 shs

Market Capitalization

$4.52 billion

P/E Ratio

14.31

Dividend Yield

N/A

Beta

0.47